期刊
JOURNAL OF HEPATOLOGY
卷 43, 期 3, 页码 458-464出版社
ELSEVIER
DOI: 10.1016/j.jhep.2005.03.033
关键词
hepatocellular carcinoma; percutaneous ethanol injection; therapy; survival; ultrasonography; computed tomography; prognosis
Background/Aims: To evaluate the therapeutic efficacy of percutaneous ethanol injection (PEI) for patients with <= 3 lesions of small (<= 3 cm diameter) hepatocellular carcinoma (HCC). Methods: PEI was applied to 270 patients with small HCC as the first-line treatment option during a 20-year period. Results: (1) There was no treatment-related deaths, and only 2.2% of severe complications; (2) PEI induced a complete response of all HCCs according to CT evaluation performed within one month after the procedure, and the local recurrence rate at 3 years was 10%; (3) the overall 3- and 5-year survival rates after treatment were 81.6 and 60.3%, respectively, but the rates were higher, 87.3 and 78.3%, in Child A patients with a solitary tumor <= 2 cm in diameter; (4) factors significantly influencing survival were liver function (P=0.0033) and serum alpha-fetoprotein level (P = 0.0014), and (5) the recurrence rate at remote sites in the liver was lower in patients with HCC <= 2 cm (P = 0.0395) and in those with a solitary HCC (P < 0.0001) according to Cox's proportional hazard model. (6) Radiofrequency ablation would not have been performed in approximately 25% of these patients. Conclusions: PEI is considered a reliable treatment for small HCC in terms of safety and efficacy. (c) 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据